NO20023266L - Antistoffer mot humant IL-1<beta> - Google Patents

Antistoffer mot humant IL-1<beta>

Info

Publication number: NO20023266L
Authority: NO; Norway
Prior art keywords: antibodies; beta; human
Prior art date: 2000-01-21

Application number

NO20023266A

Other languages

English (en)

Other versions

NO20023266D0 (no

NO329816B1 (no

Inventor

Hermann Gram

Franco E Di Padova

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-01-21

Filing date

2002-07-05

Publication date

2002-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20023266(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-07-05 Application filed by Novartis Ag filed Critical Novartis Ag

2002-07-05 Publication of NO20023266D0 publication Critical patent/NO20023266D0/no

2002-08-28 Publication of NO20023266L publication Critical patent/NO20023266L/no

2010-12-27 Publication of NO329816B1 publication Critical patent/NO329816B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
Diabetes (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Hematology (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)

NO20023266A 2000-01-21 2002-07-05 Antistoffer mot humant IL-10, anvendelse av disse, DNA konstruksjoner, ekspresjonsvektor, fremgangsmate for fremstilling og farmasoytisk sammensetning NO329816B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0001448.0A GB0001448D0 (en)	2000-01-21	2000-01-21	Organic compounds
PCT/EP2001/000591 WO2001053353A2 (en)	2000-01-21	2001-01-19	Recombinant antibodies to human interkleukin-1 beta

Publications (3)

Publication Number	Publication Date
NO20023266D0 NO20023266D0 (no)	2002-07-05
NO20023266L true NO20023266L (no)	2002-08-28
NO329816B1 NO329816B1 (no)	2010-12-27

Family

ID=9884137

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20023266A NO329816B1 (no)	2000-01-21	2002-07-05	Antistoffer mot humant IL-10, anvendelse av disse, DNA konstruksjoner, ekspresjonsvektor, fremgangsmate for fremstilling og farmasoytisk sammensetning

Country Status (33)

Country	Link
US (4)	US20030124617A1 (no)
EP (1)	EP1248804B2 (no)
JP (2)	JP3978338B2 (no)
KR (1)	KR100697126B1 (no)
CN (1)	CN1395581B (no)
AR (1)	AR027253A1 (no)
AT (1)	ATE346868T1 (no)
AU (1)	AU772949B2 (no)
BR (1)	BR0107661A (no)
CA (1)	CA2396212C (no)
CO (1)	CO5261584A1 (no)
CY (1)	CY1107989T1 (no)
CZ (1)	CZ302738B6 (no)
DE (1)	DE60124863T3 (no)
DK (1)	DK1248804T4 (no)
ES (1)	ES2274865T5 (no)
GB (1)	GB0001448D0 (no)
HK (1)	HK1050013A1 (no)
HU (1)	HUP0204156A3 (no)
IL (2)	IL150551A0 (no)
MX (1)	MXPA02007091A (no)
MY (1)	MY155269A (no)
NO (1)	NO329816B1 (no)
NZ (1)	NZ519936A (no)
PE (1)	PE20011219A1 (no)
PL (1)	PL207642B1 (no)
PT (1)	PT1248804E (no)
RU (1)	RU2264413C2 (no)
SI (1)	SI1248804T2 (no)
SK (1)	SK288054B6 (no)
TR (1)	TR200201780T2 (no)
WO (1)	WO2001053353A2 (no)
ZA (1)	ZA200205659B (no)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0001448D0 (en) *	2000-01-21	2000-03-08	Novartis Ag	Organic compounds
JP4955185B2 (ja)	2000-06-29	2012-06-20	アボット・ラボラトリーズ	二重特異性抗体ならびに作製方法および使用方法
GB0020685D0 (en)	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
CN1652821A (zh) *	2002-01-28	2005-08-10	米德列斯公司	抗前列腺特异性膜抗原(psma)的人单克隆抗体
GB0303337D0 (en)	2003-02-13	2003-03-19	Celltech R&D Ltd	Biological products
EP2287616A1 (en) *	2003-09-15	2011-02-23	Oklahoma Medical Research Foundation	Method of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
WO2006121422A2 (en)	2004-02-06	2006-11-16	University Of Massachusetts	Antibodies against clostridium difficile toxins and uses thereof
CA2590164A1 (en) *	2005-01-26	2006-08-03	Amgen Fremont Inc.	Antibodies against interleukin-1 beta
PE20061324A1 (es) *	2005-04-29	2007-01-15	Centocor Inc	Anticuerpos anti-il-6, composiciones, metodos y usos
SI2314623T1 (sl)	2005-06-21	2012-11-30	Xoma Technology Ltd	IL beta vezavna protitelesa in njihovi fragmenti
DK2848258T3 (en) *	2005-10-26	2018-03-19	Novartis Ag	Treatment of familial Mediterranean fever with anti-IL-1beta antibodies
SI2548577T1 (sl) *	2005-12-29	2017-05-31	Janssen Biotech, Inc.	Človeška protitelesa proti il-23, sestavki, postopki in uporabe
US7943328B1 (en)	2006-03-03	2011-05-17	Prometheus Laboratories Inc.	Method and system for assisting in diagnosing irritable bowel syndrome
KR20110079922A (ko) *	2006-04-14	2011-07-11	노파르티스 아게	안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US20080085524A1 (en) *	2006-08-15	2008-04-10	Prometheus Laboratories Inc.	Methods for diagnosing irritable bowel syndrome
MX2009006709A (es)	2006-12-20	2009-07-02	Xoma Technology Ltd	Tratamiento de enfermedades relacionadas con il-1beta.
EP2114443A4 (en) *	2006-12-29	2011-08-10	Abbott Lab	IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
AU2008219681A1 (en)	2007-02-28	2008-09-04	Merck Sharp & Dohme Corp.	Combination therapy for treatment of immune disorders
US8282922B2 (en) *	2007-05-29	2012-10-09	Novartis Ag	Method of treating an auto-inflammatory syndrome with a human IL-1β binding antibody
EP2391650B1 (en)	2007-12-20	2014-10-15	Xoma (Us) Llc	Methods for the treatment of gout
JP5607613B2 (ja) *	2008-06-06	2014-10-15	ゾーマ（ユーエス）リミテッドライアビリティカンパニー	関節リウマチの治療のための方法
US8545846B2 (en)	2008-09-05	2013-10-01	Xoma Technology, Ltd.	Methods for treating IL-1β related diseases by administering an anti-IL-1β antibody
DK2493922T3 (en)	2009-10-26	2017-04-24	Hoffmann La Roche	Process for preparing a glycosylated immunoglobulin
WO2011140522A1 (en)	2010-05-07	2011-11-10	Xoma Technology Ltd.	METHODS FOR THE TREATMENT OF IL-1β RELATED CONDITIONS
DE102010033565B4 (de) *	2010-07-27	2012-06-21	Tetec Tissue Engineering Technologies Ag	Marker zur Bestimmung von Chondrozyten
CN103154255B (zh)	2010-08-02	2016-04-06	瑞泽恩制药公司	制造包含vl结构域的结合蛋白的小鼠
NZ607510A (en) *	2010-09-10	2014-10-31	Apexigen Inc	Anti-il-1 beta antibodies and methods of use
RU2722373C2 (ru)	2011-02-25	2020-05-29	Редженерон Фармасьютикалс, Инк.	Мыши adam6
SI2739740T1 (sl)	2011-08-05	2019-12-31	Regeneron Pharmaceuticals, Inc.	Humanizirane univerzalne lahkoverižne miši
DE102011083595A1 (de)	2011-09-28	2013-03-28	Bayer Pharma AG	Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
CN104144946A (zh)	2011-12-19	2014-11-12	爱克索马美国有限责任公司	治疗痤疮的方法
HRP20190897T1 (hr)	2011-12-20	2019-09-20	Regeneron Pharmaceuticals, Inc.	Laki lanac humaniziranih miševa
SG11201404850SA (en)	2012-02-13	2014-09-26	Agency Science Tech & Res	IL-1β NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES
KR102484480B1 (ko)	2012-06-12	2023-01-04	리제너론 파마슈티칼스 인코포레이티드	제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
SG11201607015VA (en)	2014-03-21	2016-09-29	Regeneron Pharma	V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA3124228C (en)	2014-03-21	2024-05-14	Regeneron Pharmaceuticals, Inc.	Non-human animals that make single domain binding proteins
EP3271403A1 (en)	2015-03-19	2018-01-24	Regeneron Pharmaceuticals, Inc.	Non-human animals that select for light chain variable regions that bind antigen
WO2019171252A1 (en)	2018-03-05	2019-09-12	Janssen Biotech, Inc.	Methods of treating crohn's disease with anti-il23 specific antibody
CN110818793A (zh)	2018-08-14	2020-02-21	中山康方生物医药有限公司	抗IL-1β的抗体、其药物组合物及其用途
MA55149A (fr)	2018-11-20	2021-09-29	Janssen Biotech Inc	Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
BR112021023295A2 (pt)	2019-05-23	2022-02-08	Janssen Biotech Inc	Método de tratamento de doença inflamatória intestinal com uma terapia de combinação de anticorpos para il-23 e tnf-alfa
WO2021234634A1 (en)	2020-05-21	2021-11-25	Janssen Biotech, Inc.	Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4772685A (en)	1985-10-02	1988-09-20	Merck & Co., Inc.	Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) *	1986-08-08	1990-06-19	Syntex (U.S.A.) Inc.	Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) *	1988-12-08	1993-12-24	Commissariat A Energie Atomique	Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
US5859205A (en) *	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
JP3714683B2 (ja) *	1992-07-30	2005-11-09	生化学工業株式会社	抗リウマチ剤
US5429614A (en)	1993-06-30	1995-07-04	Baxter International Inc.	Drug delivery system
WO1995001997A1 (en) *	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en)	1998-02-19	2000-04-18	Bristol-Myers Squibb Co.	Antibodies against human CD40
GB0001448D0 (en) *	2000-01-21	2000-03-08	Novartis Ag	Organic compounds

2000
- 2000-01-21 GB GBGB0001448.0A patent/GB0001448D0/en not_active Ceased
2001
- 2001-01-18 MY MYPI20010226A patent/MY155269A/en unknown
- 2001-01-18 CO CO01003434A patent/CO5261584A1/es active IP Right Grant
- 2001-01-19 RU RU2002121649/13A patent/RU2264413C2/ru not_active IP Right Cessation
- 2001-01-19 CZ CZ20022531A patent/CZ302738B6/cs not_active IP Right Cessation
- 2001-01-19 PE PE2001000065A patent/PE20011219A1/es not_active Application Discontinuation
- 2001-01-19 HK HK03102022.5A patent/HK1050013A1/zh unknown
- 2001-01-19 DK DK01905671.2T patent/DK1248804T4/da active
- 2001-01-19 SI SI200130698T patent/SI1248804T2/sl unknown
- 2001-01-19 US US10/181,324 patent/US20030124617A1/en not_active Abandoned
- 2001-01-19 TR TR2002/01780T patent/TR200201780T2/xx unknown
- 2001-01-19 JP JP2001553825A patent/JP3978338B2/ja not_active Expired - Fee Related
- 2001-01-19 DE DE60124863T patent/DE60124863T3/de not_active Expired - Lifetime
- 2001-01-19 ES ES01905671T patent/ES2274865T5/es not_active Expired - Lifetime
- 2001-01-19 AT AT01905671T patent/ATE346868T1/de active
- 2001-01-19 AU AU33697/01A patent/AU772949B2/en not_active Ceased
- 2001-01-19 WO PCT/EP2001/000591 patent/WO2001053353A2/en not_active Ceased
- 2001-01-19 HU HU0204156A patent/HUP0204156A3/hu not_active Application Discontinuation
- 2001-01-19 SK SK1035-2002A patent/SK288054B6/sk not_active IP Right Cessation
- 2001-01-19 EP EP01905671A patent/EP1248804B2/en not_active Expired - Lifetime
- 2001-01-19 BR BR0107661-2A patent/BR0107661A/pt not_active IP Right Cessation
- 2001-01-19 AR ARP010100247A patent/AR027253A1/es active IP Right Grant
- 2001-01-19 PL PL356297A patent/PL207642B1/pl unknown
- 2001-01-19 MX MXPA02007091A patent/MXPA02007091A/es active IP Right Grant
- 2001-01-19 PT PT01905671T patent/PT1248804E/pt unknown
- 2001-01-19 CN CN018039529A patent/CN1395581B/zh not_active Expired - Fee Related
- 2001-01-19 IL IL15055101A patent/IL150551A0/xx unknown
- 2001-01-19 NZ NZ519936A patent/NZ519936A/en not_active IP Right Cessation
- 2001-01-19 KR KR1020027009374A patent/KR100697126B1/ko not_active Expired - Fee Related
- 2001-01-19 CA CA2396212A patent/CA2396212C/en not_active Expired - Fee Related
2002
- 2002-07-02 IL IL150551A patent/IL150551A/en not_active IP Right Cessation
- 2002-07-05 NO NO20023266A patent/NO329816B1/no not_active IP Right Cessation
- 2002-07-16 ZA ZA2002/05659A patent/ZA200205659B/en unknown
2006
- 2006-07-11 US US11/484,472 patent/US7491392B2/en not_active Expired - Fee Related
- 2006-12-29 CY CY20061101860T patent/CY1107989T1/el unknown
2007
- 2007-01-04 JP JP2007000148A patent/JP2007097598A/ja active Pending
2009
- 2009-01-09 US US12/351,007 patent/US20090232803A1/en not_active Abandoned
2011
- 2011-03-10 US US13/044,918 patent/US20110182894A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE60124863T3 (de)	2010-05-20
JP3978338B2 (ja)	2007-09-19
KR100697126B1 (ko)	2007-03-20
PT1248804E (pt)	2007-02-28
WO2001053353A2 (en)	2001-07-26
EP1248804A2 (en)	2002-10-16
JP2007097598A (ja)	2007-04-19
KR20020073178A (ko)	2002-09-19
IL150551A (en)	2010-11-30
IL150551A0 (en)	2003-02-12
BR0107661A (pt)	2002-11-19
CO5261584A1 (es)	2003-03-31
CN1395581A (zh)	2003-02-05
SK288054B6 (sk)	2013-03-01
SI1248804T2 (sl)	2010-04-30
ES2274865T5 (es)	2010-04-19
HUP0204156A2 (hu)	2003-03-28
US20060251660A1 (en)	2006-11-09
ATE346868T1 (de)	2006-12-15
US20030124617A1 (en)	2003-07-03
NO20023266D0 (no)	2002-07-05
EP1248804B2 (en)	2009-12-02
WO2001053353A3 (en)	2002-04-04
CN1395581B (zh)	2010-10-13
AU3369701A (en)	2001-07-31
AR027253A1 (es)	2003-03-19
PE20011219A1 (es)	2001-12-17
NZ519936A (en)	2004-02-27
ZA200205659B (en)	2003-12-31
RU2002121649A (ru)	2004-03-10
SI1248804T1 (sl)	2007-06-30
CY1107989T1 (el)	2013-09-04
JP2003520595A (ja)	2003-07-08
RU2264413C2 (ru)	2005-11-20
EP1248804B1 (en)	2006-11-29
GB0001448D0 (en)	2000-03-08
US20110182894A1 (en)	2011-07-28
CA2396212A1 (en)	2001-07-26
TR200201780T2 (tr)	2003-01-21
MY155269A (en)	2015-09-30
ES2274865T3 (es)	2007-06-01
US7491392B2 (en)	2009-02-17
DE60124863T2 (de)	2007-04-26
AU772949B2 (en)	2004-05-13
CZ20022531A3 (cs)	2002-10-16
PL207642B1 (pl)	2011-01-31
CZ302738B6 (cs)	2011-10-12
DE60124863D1 (de)	2007-01-11
HK1050013A1 (zh)	2003-06-06
CA2396212C (en)	2013-04-02
HUP0204156A3 (en)	2005-09-28
DK1248804T3 (da)	2007-02-26
NO329816B1 (no)	2010-12-27
DK1248804T4 (da)	2010-04-06
MXPA02007091A (es)	2002-12-13
SK10352002A3 (sk)	2003-03-04
PL356297A1 (en)	2004-06-28
US20090232803A1 (en)	2009-09-17

Publication	Publication Date	Title
NO20030827D0 (no)	2003-02-21	Antistoffer mot human IL-1<beta>
NO20023266L (no)	2002-08-28	Antistoffer mot humant IL-1<beta>
NO20026063L (no)	2003-02-27	Antistoffer mot human MCP-1
NO20004133D0 (no)	2000-08-18	Antistoffer mot human CD40
NO20042388L (no)	2004-08-09	Antistoff mot CD40
NO20034554L (no)	2003-12-15	Antistoffer mot VLA-1
NO20041802L (no)	2004-04-30	Antistoffer mot human vevsfaktor
NO20041018L (no)	2004-03-10	Antistoffer mot OPGL
NO20013926D0 (no)	2001-08-13	Undersjoisk intervensjon
CY2012003I2 (el)	2020-05-29	Αντισωματα που συνδεονται ανοσοειδικως προς blys
DK1857105T3 (da)	2010-09-20	Kathartisk præparat
DE60129523D1 (de)	2007-09-06	Wegwerfunterwäsche
AU4835001A (en)	2001-09-24	Antibodies to human cd154
DK1049717T3 (da)	2007-07-30	Antistoffer mod human IL-2
DE60137900D1 (de)	2009-04-23	Wegwerfunterwäsche
FI20000416L (fi)	2001-08-23	Ihmiselimistöön liittyvä mittaus
DE60129917D1 (de)	2007-09-27	Wegwerfunterwäsche
DE60142667D1 (de)	2010-09-09	Wegwerfunterwäsche
DE60113590D1 (de)	2006-02-09	Wegwerfunterwäsche
AR028262A1 (es)	2003-04-30	Anticuerpos especificos de fap-alfa humanos
UA5902S (uk)	2002-04-15	Сечозбірник

Legal Events

Date	Code	Title	Description
2014-08-25	MM1K	Lapsed by not paying the annual fees